Zevra Therapeutics (ZVRA) Tax Provisions (2014 - 2026)

Zevra Therapeutics (ZVRA) has 13 years of Tax Provisions data on file, last reported at $6.9 million in Q1 2026.

• Quarterly Tax Provisions rose 484.94% year-over-year to $6.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.2 million (down 44.77% YoY) and the FY2025 annual result came in at $3.4 million, down 77.56% from the prior year.
• Tax Provisions climbed to $6.9 million in Q1 2026, from $501000.0 in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of $15.4 million in Q4 2024 to a low of -$433000.0 in Q3 2025.
• A 5-year average of $1.8 million and a median of $54000.0 in 2022 frame the typical range for Tax Provisions.
• Annual changes were most pronounced in 2023 — Tax Provisions sank 2475.0% — and 2025, when it soared 3041.43%.
• Tracing ZVRA's Tax Provisions over 5 years: stood at -$34000.0 in 2022, then surged by 620.59% to $177000.0 in 2023, then surged by 8584.18% to $15.4 million in 2024, then plunged by 96.74% to $501000.0 in 2025, then surged by 1280.04% to $6.9 million in 2026.
• The last three Tax Provisions figures came in at $6.9 million (Q1 2026), $501000.0 (Q4 2025), and -$433000.0 (Q3 2025), per Business Quant data.